Published in Antimicrob Agents Chemother on November 25, 2013
Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother (2014) 1.19
Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs (2014) 1.06
Colistin for lung infection: an update. J Intensive Care (2015) 1.03
Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother (2015) 0.96
Carbapenemase-producing Klebsiella pneumoniae. F1000Prime Rep (2014) 0.91
A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii. Infect Dis Ther (2014) 0.91
In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother (2014) 0.91
Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy (2015) 0.86
Comparative and genetic analysis of the four sequenced Paenibacillus polymyxa genomes reveals a diverse metabolism and conservation of genes relevant to plant-growth promotion and competitiveness. BMC Genomics (2014) 0.84
How to treat VAP due to MDR pathogens in ICU patients. BMC Infect Dis (2014) 0.81
Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections. Clin Infect Dis (2014) 0.81
The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. BMC Infect Dis (2015) 0.78
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin Microbiol Rev (2017) 0.76
Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infect Dis Ther (2015) 0.75
Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia. Eur J Clin Microbiol Infect Dis (2016) 0.75
Synergistic combinations of polymyxins. Int J Antimicrob Agents (2016) 0.75
In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2015) 0.75
Antibiotic resistance of pathogenic Acinetobacter species and emerging combination therapy. J Microbiol (2017) 0.75
Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections. Infect Dis Ther (2017) 0.75
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med (2013) 39.56
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis (2012) 4.62
The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med (2005) 4.07
Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis (2009) 3.92
Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother (2009) 3.62
The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol (2006) 3.27
High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis (2012) 2.92
High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect (2012) 1.92
Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother (2010) 1.89
Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med (2008) 1.69
Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther (2013) 1.36
In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother (2011) 1.25
In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother (2011) 1.24
Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains. Antimicrob Agents Chemother (2013) 1.17
Old antibiotics for infections in critically ill patients. Curr Opin Crit Care (2007) 1.14
The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res (2006) 1.14
Confronting the threat of multidrug-resistant Gram-negative bacteria in critically ill patients. J Antimicrob Chemother (2012) 1.10
Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect (2011) 1.08
In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother (2012) 1.03
Management of antibiotic resistance in the intensive care unit setting. Expert Rev Anti Infect Ther (2010) 0.84
Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA (2005) 7.41
Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med (2014) 7.07
Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA (2009) 6.55
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med (2014) 3.56
Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med (2014) 3.37
Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med (2007) 3.34
Early vs late tracheotomy for prevention of pneumonia in mechanically ventilated adult ICU patients: a randomized controlled trial. JAMA (2010) 3.20
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med (2012) 3.18
Challenges in end-of-life care in the ICU. Statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003. Intensive Care Med (2004) 3.16
Usefulness of transcranial echography in patients with decompressive craniectomy: a comparison with computed tomography scan. Crit Care Med (2012) 3.10
Challenges in end-of-life care in the ICU: statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003: executive summary. Crit Care Med (2004) 2.95
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation (2015) 2.84
In-hospital cardiac arrest: incidence, prognosis and possible measures to improve survival. Intensive Care Med (2006) 2.72
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents (2007) 2.61
Evaluation of patient skin breakdown and comfort with a new face mask for non-invasive ventilation: a multi-center study. Intensive Care Med (2002) 2.46
Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis (2009) 2.39
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis (2012) 2.34
The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks. Intensive Care Med (2011) 2.28
Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med (2014) 2.05
Euthanasia, therapeutic obstinacy or something else? An Italian case. Intensive Care Med (2005) 2.03
Noninvasive versus invasive ventilation for acute respiratory failure in patients with hematologic malignancies: a 5-year multicenter observational survey. Crit Care Med (2011) 1.96
A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc (2013) 1.77
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med (2004) 1.72
Noninvasive ventilation after early extubation in patients recovering from hypoxemic acute respiratory failure: a single-centre feasibility study. Intensive Care Med (2012) 1.63
Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care (2013) 1.60
Diagnostic accuracy of passive leg raising for prediction of fluid responsiveness in adults: systematic review and meta-analysis of clinical studies. Intensive Care Med (2010) 1.58
Direct maldi-tof mass spectrometry assay of blood culture broths for rapid identification of Candida species causing bloodstream infections: an observational study in two large microbiology laboratories. J Clin Microbiol (2011) 1.58
Noninvasive positive-pressure ventilation with different interfaces in patients with respiratory failure after abdominal surgery: a matched-control study. Respir Care (2007) 1.57
A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med (2010) 1.56
Ventilator-associated pneumonia: current status and future recommendations. J Clin Monit Comput (2010) 1.54
A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med (2015) 1.54
Online vs live methods for teaching difficult airway management to anesthesiology residents. Intensive Care Med (2005) 1.51
Non-invasive ventilation delivered by conventional interfaces and helmet in the emergency department. Eur J Emerg Med (2003) 1.51
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med (2012) 1.47
Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother (2010) 1.47
Levels of vancomycin in the cerebral interstitial fluid after severe head injury. Intensive Care Med (2006) 1.46
In-hospital cardiac arrest: survival depends mainly on the effectiveness of the emergency response. Resuscitation (2004) 1.41
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. EuroIntervention (2014) 1.41
Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother (2009) 1.40
Noninvasive ventilation options in pediatric myasthenia gravis. Paediatr Anaesth (2005) 1.39
Immunonutrients in critically ill patients: an analysis of the most recent literature. Minerva Anestesiol (2015) 1.39
Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother (2011) 1.39
Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Crit Care (2011) 1.38
Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther (2013) 1.36
Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med (2015) 1.34
Developing and evaluating professionalism. Med Teach (2006) 1.31
The epidemiology of acute respiratory failure in critically ill patients(*). Chest (2002) 1.29
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother (2008) 1.27
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica (2013) 1.26
The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J (2007) 1.26
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care (2014) 1.25
Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med (2013) 1.24
Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema--a systematic review and meta-analysis. Crit Care (2006) 1.23
The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica (2011) 1.23
Vitamin D status in critically ill patients: the evidence is now bioavailable! Crit Care (2014) 1.23
Hydroxyethyl starch for intravenous volume replacement: more harm than benefit. JAMA (2013) 1.22
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev (2013) 1.21
Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J Antimicrob Chemother (2006) 1.20
Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis (2010) 1.20
Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J Antimicrob Chemother (2005) 1.19
Incidence and risk factors for ventilator-associated pneumonia after major heart surgery. Intensive Care Med (2009) 1.19
Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother (2011) 1.18
Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis (2007) 1.17
Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. Arch Intern Med (2008) 1.16
Noninvasive vs invasive ventilation in COPD patients with severe acute respiratory failure deemed to require ventilatory assistance. Intensive Care Med (2004) 1.15
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med (2017) 1.15
Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol (2011) 1.15
Should lower respiratory tract secretions from intensive care patients be systematically screened for influenza virus during the influenza season? Crit Care (2012) 1.14
Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther (2013) 1.13
Noninvasive versus conventional ventilation to treat hypercapnic encephalopathy in chronic obstructive pulmonary disease. Intensive Care Med (2007) 1.12
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg Infect Dis (2002) 1.12
Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol (2013) 1.10
A prospective, blinded evaluation of indexes proposed to predict weaning from mechanical ventilation. Intensive Care Med (2004) 1.10
A low-dose remifentanil infusion is well tolerated for sedation in mechanically ventilated, critically-ill patients. Can J Anaesth (2002) 1.09
Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. J Clin Microbiol (2006) 1.07
Detecting risk and predicting patient mortality in patients with extended-spectrum β-lactamase-producing Enterobacteriaceae bloodstream infections. Future Microbiol (2012) 1.07
Levosimendan in Cardiac Surgery. N Engl J Med (2017) 1.06
Rhodococcus equi infection in HIV-infected individuals: case reports and review of the literature. AIDS Patient Care STDS (2010) 1.06
Buffered crystalloids and acid-base state: still searching the optimal balance? Minerva Anestesiol (2015) 1.06
Effects of PEEP on the intracranial system of patients with head injury and subarachnoid hemorrhage: the role of respiratory system compliance. J Trauma (2005) 1.06